Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Ann Mullally: Expect to See Lots More Gene Therapy in Medicine in the Years Ahead
Ann Mullally/med.stanford.edu and Katherine High/rhygaze.com
Sep 28, 2026, 01:51

Ann Mullally: Expect to See Lots More Gene Therapy in Medicine in the Years Ahead

Ann Mullally, Professor at Stanford University School of Medicine, Division Chief of Hematology at Stanford Department of Medicine, Principal Investigator at Mullally Lab, shared Stanford Department of Medicine‘s post on LinkedIn:

“Expect to see lots more gene therapy in medicine in the years ahead!

One of many inspiring messages from Katherine High during her visit to Stanford Division of Hematology this week – a trailblazer in treating hemophilia with gene therapy, it was an honor to host Dr. High with Stanford Department of Medicine and to learn more about her pioneering work and exciting career!”

Stanford Department of Medicine shared a post on LinkedIn:

“Gene therapy pioneer Katherine High, delivered the Stanley Schrier Lecture at this week’s Medicine Grand Rounds.

High is the co-founder of Spark Therapeutics, Inc., winner of the 2026 Breakthrough Prize in Life Sciences and leader of the team that won FDA approval for Luxturna, the first gene therapy for an inherited disease.”

Ann Mullally

Stay updated with Hemostasis Today.

Ann Mullally bleeding bleeding disorders Blood FDA Gene therapy Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today High Katherine High Luxturna Medicine Medicine Grand Rounds Spark Therapeutics Stanford Division of Hematology Stanley Schrier
NewsFeed